Skip to main content
Journal cover image

Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.

Publication ,  Journal Article
Lyle, MA; Iyer, SR; Redfield, MM; Reddy, YNV; Felker, GM; Cappola, TP; Hernandez, AF; Scott, CG; Burnett, JC; Pereira, NL
Published in: JACC Heart Fail
January 2020

BACKGROUND: In heart failure with reduced ejection fraction (HFrEF), elevated soluble neprilysin (sNEP) levels are associated with an increased risk of cardiovascular death, and its inhibition with sacubitril/valsartan has improved survival. OBJECTIVES: This study sought to determine the relevance of sNEP as a biomarker in heart failure with preserved ejection fraction (HFpEF) and to compare circulating sNEP levels in patients with HFpEF with normal controls. METHODS: A case-control study was performed in 242 symptomatic patients with HFpEF previously enrolled in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) and Nitrates's Effect on Activity Tolerance in Heart Failure With Preserved Ejection (NEAT-HFpEF) clinical trials and 891 asymptomatic subjects without HF or diastolic dysfunction (confirmed by NT-proBNP levels <200 pg/ml and echocardiography) who were enrolled in the Prevalence of Asymptomatic Left Ventricular Dysfunction study. sNEP was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) in all subjects. RESULTS: Overall, sNEP levels were lower in HFpEF compared with controls (3.5 ng/ml; confidence interval [CI]: 2.5 to 4.8 vs. 8.5 ng/ml; CI: 7.2 to 10.0; p < 0.001). After adjusting for age, gender, body mass index (BMI), and smoking history, mean sNEP levels were also lower in HFpEF compared with controls (4.0 ng/ml [CI: 2.7 to 5.4] vs. 8.2 ng/ml [CI: 6.8 to 9.7]; p = 0.002). The cohorts were propensity matched based on age, BMI, diabetes, hypertension, smoking history, and renal function, and sNEP levels remained lower in HFpEF compared with controls (median 2.4 ng/ml [interquartile range: 0.6 to 27.7] vs. 4.9 ng/ml [interquartile range: 1.2 to 42.2]; p = 0.02). CONCLUSIONS: Patients with HFpEF on average have significantly lower circulating sNEP levels compared with controls. These findings challenge our current understanding of the complex biology of circulating sNEP in HFpEF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

January 2020

Volume

8

Issue

1

Start / End Page

70 / 80

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Neprilysin
  • Middle Aged
  • Male
  • Humans
  • Heart Ventricles
  • Heart Failure
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyle, M. A., Iyer, S. R., Redfield, M. M., Reddy, Y. N. V., Felker, G. M., Cappola, T. P., … Pereira, N. L. (2020). Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail, 8(1), 70–80. https://doi.org/10.1016/j.jchf.2019.07.005
Lyle, Melissa A., Seethalakshmi R. Iyer, Margaret M. Redfield, Yogesh N. V. Reddy, G Michael Felker, Thomas P. Cappola, Adrian F. Hernandez, Christopher G. Scott, John C. Burnett, and Naveen L. Pereira. “Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.JACC Heart Fail 8, no. 1 (January 2020): 70–80. https://doi.org/10.1016/j.jchf.2019.07.005.
Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, et al. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2020 Jan;8(1):70–80.
Lyle, Melissa A., et al. “Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.JACC Heart Fail, vol. 8, no. 1, Jan. 2020, pp. 70–80. Pubmed, doi:10.1016/j.jchf.2019.07.005.
Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Scott CG, Burnett JC, Pereira NL. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2020 Jan;8(1):70–80.
Journal cover image

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

January 2020

Volume

8

Issue

1

Start / End Page

70 / 80

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Neprilysin
  • Middle Aged
  • Male
  • Humans
  • Heart Ventricles
  • Heart Failure